MedTrace Logo

AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver

NCT01361061 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2018-10-11

No results posted yet for this study

Summary

Hepatocellular carcinoma (HCC) is one of the tumors with a rising incidence worldwide. The aim of this trial is to improve the detection of early HCC nodules in the liver. At the moment screening for HCC in patients with liver cirrhosis is performed by ultrasound and measurement of alpha- fetoprotein (AFP). In this trail the tumor markers AFP- L3 (a subfraction of AFP) and Des-y- carboxyprothromib (DCP) are measured in addition in order to receive information about the course of these markers before the detection of a HCC nodule.

Conditions

Sponsors & Collaborators

  • Wako Diagnostics

    collaborator INDUSTRY

  • Johannes Gutenberg University Mainz

    collaborator OTHER

  • University Hospital Heidelberg

    collaborator OTHER

  • University Hospital Freiburg

    lead OTHER

Principal Investigators

  • Hans Christian Spangenberg, Prof. Dr. · University Medical Center Freiburg

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01361061 on ClinicalTrials.gov